A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-26 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
== History == The origin of the term food noise is unknown, but it first appeared in a Google search in 2006. Google searches for “food noise” increased markedly in 2022, possibly due to the rising use of GLP-1 receptor agonist drugs (GLP-1 RA drugs) for weight loss. Growing public interest spurred attention from researchers, and the concept was first incorporated into a model of food cue reactivity (how the body and brain respond when a person sees, smells, or thinks about food) in 2023. However, other researchers do not see food cue reactivity as the sole trigger for food noise.
The energy transferred by electrons flowing through this electron transport chain is used to transport protons across the inner membrane. This generates potential energy in the form of a pH gradient and the resulting electrical potential across this membrane. This store of energy is tapped when protons flow back across the membrane through ATP synthase in a process called chemiosmosis. The ATP synthase uses the energy to transform adenosine diphosphate (ADP) into adenosine triphosphate, in a phosphorylation reaction. The reaction is driven by the proton flow, which forces the rotation of a part of the enzyme. The ATP synthase is a rotary mechanical motor. Although oxidative phosphorylation is a vital part of metabolism, it produces reactive oxygen species such as superoxide and hydrogen peroxide, which lead to propagation of free radicals, damaging cells and contributing to disease and, possibly, aging and senescence. The enzymes carrying out this metabolic pathway are also the target of many drugs and poisons that inhibit their activities.
These kingdoms were defined as "the viceroyalties of New Spain (Mexico), Peru, New Granada, and Buenos Aires, and the independent captaincies general of the island of Cuba, Puerto Rico, Guatemala, Chile, Province of Venezuela, and the Philippines." This plan was criticized for providing unequal representation to Spanish America; nevertheless, throughout the end of 1808 and early 1809, the regional capitals elected candidates, whose names were forwarded to the capitals of the viceroyalties or captaincies general. Several important and large cities were left without direct representation in the Supreme Junta. In particular Quito and Chuquisaca, which saw themselves as the capitals of kingdoms, resented being subsumed in the larger Viceroyalty of Peru and Viceroyalty of the Río de la Plata respectively. This unrest led to the establishment of juntas in these cities in 1809, which were eventually quashed by the authorities within the year. An unsuccessful attempt at establishing a junta in New Spain was also stopped.
Although IV and oral acetylcysteine are equally effective for this indication, oral administration is generally poorly tolerated due to the higher dosing required to overcome its low oral bioavailability, its foul taste and odor, and a higher incidence of adverse effects when taken orally, particularly nausea and vomiting. Prior pharmacokinetic studies of acetylcysteine did not consider acetylation as a reason for the low bioavailability of acetylcysteine. Oral acetylcysteine is identical in bioavailability to cysteine precursors. However, 3% to 6% of people given intravenous acetylcysteine show a severe, anaphylaxis-like allergic reaction, which may include extreme breathing difficulty (due to bronchospasm), a decrease in blood pressure, rash, angioedema, and sometimes also nausea and vomiting. Repeated doses of intravenous acetylcysteine will cause these allergic reactions to progressively worsen in these people. Several studies have found this anaphylaxis-like reaction to occur more often in people given intravenous acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic.
Sources: en.wikipedia.org
The system was deliberately developed using existing commercially available technology to speed introduction. The development team could not afford the time to develop and debug new technology. Watt, a pragmatic engineer, believed "third-best" would do if "second-best" would not be available in time and "best" never available at all. This led to the use of the 50 m wavelength (around 6 MHz), which Wilkins suggested would resonate in a bomber's wings and improve the signal. Unfortunately, this also meant that the system was increasingly blanketed by noise as new commercial broadcasts began taking up this formerly high-frequency spectrum. The team responded by reducing their own wavelength to 26 m (around 11 MHz) to get clear spectrum. To everyone's delight, and contrary to Wilkins' 1935 calculations, the shorter wavelength produced no loss of performance. This led to a further reduction to 13 m, and finally the ability to tune between 10 and 13 m, (roughly 30-20 MHz) to provide some frequency agility to help avoid jamming. Wilkins' method of height-finding was added in 1937. He had originally developed this system as a way to measure the vertical angle of transatlantic broadcasts while working at the RRS. The system consisted of several parallel dipoles separated vertically on the receiver masts. Normally the RDF goniometer was connected to two crossed dipoles at the same height and used to determine the bearing to a target return.
=== Alloplastic grafts === Alloplastic grafts may be made from hydroxyapatite, a naturally occurring mineral that is also the main mineral component of bone. They may be made from bioactive glass. Hydroxylapatite is a synthetic bone graft, which is the most used now among other synthetic due to its osteoconduction, hardness and acceptability by bone. Tricalcium phosphate which is now used in combination with hydroxylapatite thus give both effect osteoconduction and resorbability. Polymers such as some microporous grades of PMMA and various other acrylates (such as polyhydroxylethylmethacrylate aka PHEMA), coated with calcium hydroxide for adhesion, are also used as alloplastic grafts for their inhibition of infection and their mechanical resilience and biocompatibility. Calcifying marine algae such as Corallina officinalis have a fluorohydroxyapatitic composition whose structure is similar to human bone and offers gradual resorption, thus it is treated and standardized as "FHA (Fluoro-hydroxy-apatitic) biomaterial" alloplastic bone grafts.
=== Thirlwall inquiry === After Letby's conviction, the British government announced an independent inquiry into "the circumstances surrounding the deaths and incidents, including how concerns raised by clinicians were dealt with". It was initially established on a non‑statutory basis, meaning witnesses could not be compelled to give evidence and inquests would still be required. Senior figures at the Countess of Chester Hospital, including the medical director, chief executive and nursing director at the time of the incidents, said they would cooperate. The medical director retired in August 2018, and the chief executive resigned the following month after signing a non‑disclosure agreement. Families represented by the law firm Slater and Gordon called for the inquiry to be given statutory powers, arguing that a non‑statutory process relied on the goodwill of witnesses. Similar calls were made by former Justice Secretary Sir Robert Buckland, Chester MP Samantha Dixon, Steve Brine, chair of the Health and Social Care Select Committee, Sir Keir Starmer, then Leader of the Opposition, and the Parliamentary and Health Service Ombudsman. In August 2024, a group of 24 neonatal and statistical experts wrote to ministers requesting that the inquiry be postponed and its terms amended, citing concerns about the safety of Letby's convictions. The inquiry declined to make changes. Education Secretary Gillian Keegan said the type of inquiry would be reviewed once a chair was appointed.
The history of penicillin traces how observations of antibiotic activity in the mould Penicillium led to the development of penicillins, a family of widely used antibiotics. Ancient societies used moulds to treat infections, and many people observed the inhibition of bacterial growth by moulds. While working at St Mary's Hospital in London in 1928, Scottish physician Alexander Fleming was the first to show experimentally that a Penicillium mould secretes an antibacterial substance, which he named "penicillin". The mould was found to be a variant of Penicillium chrysogenum (now called Penicillium rubens), a contaminant of a bacterial culture in his laboratory. The work on penicillin at St Mary's ended in 1929. In 1939, a team of scientists at the Sir William Dunn School of Pathology at the University of Oxford, led by Howard Florey, which included Edward Abraham, Ernst Chain, Mary Ethel Florey, Norman Heatley and Margaret Jennings, began researching penicillin. They developed a method for cultivating the mould and extracting, purifying and storing penicillin from it, together with an assay for measuring its purity. "Penicillin" now became the name of the active ingredient in the mould juice. They carried out experiments on animals to determine penicillin's safety and effectiveness before conducting clinical trials and field tests. They derived penicillin's chemical formula and determined how it works. The private sector and the United States Department of Agriculture located and produced new strains and developed mass production techniques.
Large farms: When a digital agriculture technology requires much upfront investment, only large farms with sufficient assets and credit access will adopt it. For example, large farms are most likely to adopt precision agriculture technologies because of high costs. Increasingly however, automated mechanization is focusing on more but smaller autonomous machines, instead of fewer but larger machines such as observed with machines that still require human control. This trend enables smaller farms to participate in digital agriculture more evenly with larger farms, as the upfront investment becomes more equal relative to the size of the farm. Digital divide: The uneven access to information and communication technologies (ICTs) may lead to uneven adoption of, and thereby uneven gains from, digital agriculture. When digital technologies require specific skills, benefits may accrue to digitally literate farmers positioned to take advantage of such opportunities. Gender: Given gender-based disparities in ICT access and the gender gap in agribusiness value chains, men seem more likely to adopt digital agriculture. Therefore, digital technologies could perpetuate gender inequalities in the agricultural sector. Unskilled labor: Advances in on-farm productivity, particularly through digitized automation and precision agriculture, may threaten low-skilled jobs. According to the OECD, agriculture will be one of the sectors most affected by automation and McKinsey Global Institute projects that automation will displace 15% of agricultural workers in Mexico and 30% in Germany.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.